HIGHLIGHTS
- who: Deepali Pal from the Clinical Research Institute University, Herschel Building Level, Brewery Lane, Newcastle upon Tyne, RU UK have published the article: hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia, in the Journal: (JOURNAL) of August/16,/2022
- what: The authors develop human induced pluripotent stem cell (hiPSC)-engineered niches to reveal druggable cancer-niche dependencies. The authors show comparable gene_expression profiles between iMSC and BM-MSC . The authors show that ADH-1 fails to show a drug dose response in ALL and AML cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.